ReviewThe Journal of pharmacology and experimental therapeutics2025
Mini-review: Human N-acetyltransferase genetic polymorphisms in susceptibility to aromatic amine and alkylaniline genotoxicity.
Review in The Journal of pharmacology and experimental therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Arylamine N-acetyltransferases are xenobiotic metabolizing enzymes which play a significant role in the metabolism and detoxification of many drugs and carcinogens. Two N-acetyltransferases have been characterized in humans with similar structure but different substrate affinity. N-acetyltransferase 1 (NAT1) is found in many tissues, whereas N-acetyltransferase 2 (NAT2) is found mostly in the liver and gastrointestinal tract. Both NATs are polymorphic and catalyze both N-acetylation (usually deactivation) and O-acetylation (usually activation) of aromatic amine carcinogens. Previous studies, done in bacteria or animals, have reported that exposure to aromatic amines and alkylanilines leads to DNA damage and mutations. Mammalian models transfected with recombinant human NAT alleles have been constructed to investigate the role of NAT polymorphisms in metabolism or genotoxicity of these carcinogens. This mini-review describes biological plausibility for aromatic amine and alkylaniline carcinogenicity that further supports NAT polymorphisms as important factors for aromatic amine and alkylaniline risk assessments. SIGNIFICANCE STATEMENT: This mini-review describes biological plausibility for aromatic amine and alkylaniline carcinogenicity. N-acetyltransferase polymorphisms are important factors for aromatic amine and alkylaniline risk assessments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.